Journal article
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Abstract
BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.
METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary …
Authors
Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS
Journal
The New England Journal of Medicine, Vol. 377, No. 14, pp. 1319–1330
Publisher
Massachusetts Medical Society
Publication Date
October 5, 2017
DOI
10.1056/nejmoa1709118
ISSN
0028-4793